Overall survival prediction models for gynecological endometrioid adenocarcinoma with squamous differentiation (GE-ASqD) using machine-learning algorithms

[1]  Prahlad T. Ram,et al.  Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics , 2022, JAMA network open.

[2]  Shanshan Cheng,et al.  Artificial intelligence-based preoperative prediction system for diagnosis and prognosis in epithelial ovarian cancer: A multicenter study , 2022, Frontiers in Oncology.

[3]  H. Gao,et al.  A deep learning-based automatic staging method for early endometrial cancer on MRI images , 2022, Frontiers in Physiology.

[4]  D. Castrillon,et al.  Prevalence and prognostic significance of PD-L1, TIM-3 and B7-H3 expression in endometrial serous carcinoma , 2022, Modern Pathology.

[5]  Songfa Zhang,et al.  PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance , 2021, Cancer management and research.

[6]  San-Gang Wu,et al.  Long-Term Survival Among Histological Subtypes in Advanced Epithelial Ovarian Cancer: Population-Based Study Using the Surveillance, Epidemiology, and End Results Database , 2021, JMIR public health and surveillance.

[7]  D. Mutch,et al.  NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  Dechang Chen,et al.  A prognostic system for epithelial ovarian carcinomas using machine learning , 2021, Acta obstetricia et gynecologica Scandinavica.

[9]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[10]  D. Matei,et al.  Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[11]  A. Oza,et al.  Advances in ovarian cancer, from biology to treatment , 2021, Nature Cancer.

[12]  S. Pignata,et al.  PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives , 2020, Cancer management and research.

[13]  L. Insabato,et al.  Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups , 2020, Archives of Gynecology and Obstetrics.

[14]  H. Putter,et al.  Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial , 2019, The Lancet. Oncology.

[15]  R. Reis,et al.  Squamous differentiation portends poor prognosis in low and intermediate-risk endometrioid endometrial cancer , 2019, bioRxiv.

[16]  M. Pike,et al.  Ovarian Cancer in Women of African Ancestry (OCWAA) consortium: a resource of harmonized data from eight epidemiologic studies of African American and white women , 2019, Cancer Causes & Control.

[17]  W. E. Richards,et al.  Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. , 2019, The New England journal of medicine.

[18]  C. Sessa,et al.  Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  M. Munsell,et al.  A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. , 2017, Gynecologic oncology.

[20]  J. Ledermann,et al.  ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer , 2015, International Journal of Gynecologic Cancer.

[21]  B. Long,et al.  Disparities in uterine cancer epidemiology, treatment, and survival among African Americans in the United States. , 2013, Gynecologic oncology.

[22]  S. Leung,et al.  Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas , 2013, The American journal of surgical pathology.

[23]  J. Prat.  New insights into ovarian cancer pathology. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  H. Chung,et al.  Preoperative identification of a low-risk group for lymph node metastasis in endometrial cancer: a Korean gynecologic oncology group study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  F. Nogales,et al.  Endometrial metaplasias and reactive changes: a spectrum of altered differentiation , 2010, Journal of Clinical Pathology.

[26]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[27]  D. Jung,et al.  Preoperative Prediction Model of Lymph Node Metastasis in Endometrial Cancer , 2010, International Journal of Gynecologic Cancer.

[28]  C. Sessa,et al.  Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  M. Parmar,et al.  Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study , 2009, The Lancet.

[30]  Jens Einenkel,et al.  Histopathology of endometrial hyperplasia and endometrial carcinoma: an update. , 2007, Annals of diagnostic pathology.

[31]  J. Risinger,et al.  Racial disparities in blacks with gynecologic cancers , 2007, Cancer.

[32]  N. Sakuragi,et al.  Combined use of magnetic resonance imaging, CA 125 assay, histologic type, and histologic grade in the prediction of lymph node metastasis in endometrial carcinoma. , 2003, American journal of obstetrics and gynecology.

[33]  D. Herbold,et al.  The significance of squamous differentiation in endometrial carcinoma. Data from a gynecologic oncology group study , 1991, Cancer.

[34]  E. Atkinson,et al.  Endometrioid carcinoma of the ovary: retrospective review of 145 cases. , 1990 .

[35]  H. Taylor,et al.  ENDOMETRIOID CARCINOMA OF THE OVARY. , 1964, American journal of obstetrics and gynecology.

[36]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.